Convalescent plasma therapy in patients with COVID-19.
Convalescent plasma therapy in patients with COVID-19.
复制标题
DOI：
10.1016/j.transci.2020.102955
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Celik O
中科院分区：
文献类型：
--
作者：
Altuntas F;Ata N;Yigenoglu TN;Bascı S;Dal MS;Korkmaz S;Namdaroglu S;Basturk A;Hacıbekiroglu T;Dogu MH;Berber İ;Dal K;Kınık K;Haznedaroglu İ;Yılmaz FM;Kılıç İ;Demircioğlu S;Yosunkaya A;Erkurt MA;Turgut B;Caglayan M;Celik O
被动抗体疗法已被用于使易受感染的人免于感染。在本研究中，我们旨在探讨恢复期血浆（CP）治疗COVID-19重症和危重症患者的疗效。回顾性分析接受抗sars - cov -2抗体CP联合抗病毒治疗的重症或危重症患者（n = 888），以及按1:1比例匹配重症或危重症患者（n = 888）的年龄、性别、合并症和其他治疗方法的资料。CP组患者在重症监护病房（ICU）停留时间、机械通气（MV）支持率和血管加压素支持率均低于对照组（p = 0.001, p = 0.02, p = 0.001）。CP组病死率（CFR）为24.7%，对照组为27.7%。与前3个间隔组（≤5天，6 - 10天，11 - 15天）相比，在COVID-19诊断或COVID-19相关症状后20天给予CP与更高的MV支持率相关（p=0.001）。CP治疗似乎对重症和危重症患者的COVID-19病程更好。
Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and critically ill patients diagnosed with COVID-19. The data of severe or critically ill COVID-19 patients who received anti-SARS-CoV-2 antibody-containing CP along with the antiviral treatment (n = 888) and an age-gender, comorbidity, and other COVID-19 treatments matched severe or critically ill COVID-19 patients at 1:1 ratio (n = 888) were analyzed retrospectively. Duration in the intensive care unit (ICU), the rate of mechanical ventilation (MV) support and vasopressor support were lower in CP group compared with the control group (p = 0.001, p = 0.02, p = 0.001, respectively). The case fatality rate (CFR) was 24.7 % in the CP group, and it was 27.7 % in the control group. Administration of CP 20 days after the COVID-19 diagnosis or COVID-19 related symptoms were associated with a higher rate of MV support compared with the first 3 interval groups (≤5 days, 6−10 days, 11−15 days) (p=0.001). CP therapy seems to be effective for a better course of COVID-19 in severe and critically ill patients.
登录
查看更多内容
影响因子：
158.5
作者：
Li, Qun;Guan, Xuhua;Feng, Zijian
通讯作者：
Feng, Zijian
影响因子：
28.3
作者：
Gorbalenya, Alexander E.;Baker, Susan C.;Ziebuhr, John
通讯作者：
Ziebuhr, John
DOI：
10.1007/s10096-004-1271-9
发表时间：
2005-01
期刊：
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
影响因子：
--
作者：
Cheng Y;Wong R;Soo YO;Wong WS;Lee CK;Ng MH;Chan P;Wong KC;Leung CB;Cheng G
通讯作者：
Cheng G
影响因子：
120.7
作者：
Li, Ling;Zhang, Wei;Liu, Zhong
通讯作者：
Liu, Zhong
DOI：
10.1016/j.ijantimicag.2020.105949
发表时间：
2020-07-01
影响因子：
10.8
作者：
Gautret, Philippe;Lagier, Jean-Christophe;Raoult, Didier
通讯作者：
Raoult, Didier